The end of a decade-long wait
Pharmaco (NZ) Ltd welcomes the start of PHARMAC funding for Utrogestan® (micronised progesterone), which begins today.
The funding means thousands of Kiwi women now have access to this medication, which when combined with an oestrogen can
help reduce menopausal symptoms.
Utrogestan is indicated for Menopausal Hormone Therapy (MHT – also known as HRT) alongside oestrogen in postmenopausal
women with an intact uterus. In reviewing the application for funding, the PHARMAC Endocrinology Subcommittee noted that
providing wider access to Utrogestan could help address the lack of treatment for patients who cannot tolerate currently
funded options. The subcommittee also noted the health risks and health needs of Māori and Pacifica women who are at an
increased risk of early menopause.
The start of funding of progesterone has been welcomed by Christchurch endocrinologist Dr. Anna Fenton, who says: “This decision by PHARMAC provides more equitable access to a form of progesterone which is identical to the
body’s natural form. Menopause is not a quick process and for many women it can have significant impact on their quality
of life. This announcement now allows women to potentially have greater choice and access to medication that may meet
their needs. It is really good news.”
Christine Ivers, Head of Digital and Marketing at Pharmaco (NZ) Limited, adds: “The growing body of science shows that use of Menopausal Hormone Therapy (MHT –
previously known as HRT) can potentially help improve quality of life and may be associated with fewer women having
severe symptoms that can impact on their ability to work.
We therefore encourage women to speak to their GPs if they think they are experiencing symptoms of menopause. They can
then explore how newly funded medicines, such as Utrogestan, might help benefit their quality of life.”
Notes to Editors:About Utrogestan
UTROGESTAN IS A PRESCRIPTION MEDICINE
Utrogestan is a soft capsule containing 100 mg of progesterone.
Utrogestan capsules are for use in combination with oestrogen in post-menopausal women with an intact uterus (womb), for
hormone replacement therapy. For oral use only.
Do not use Utrogestan if you have an allergy to any medicine containing progesterone. Do not use Utrogestan if you have
any of the following conditions: unusual vaginal bleeding, severe liver problems, known or suspected cancer of the
breast or genital tract, blood clots, bleeding on the brain, porphyria. Do not take Utrogestan if you are pregnant or
intend to become pregnant or if you are breastfeeding.
Further information on the risks and benefits of this medicine can be found in the Consumer Medicines Information (CMI).
Please refer to www.medsafe.govt.nz or your pharmacist for a copy of the CMI.